Core Insights - Vaximm AG has appointed Sébastien Wieckowski, PhD, as Chief Scientific Officer, enhancing its leadership in oral T-cell immunotherapies for cancer [1][3] - Dr. Wieckowski's multidisciplinary background in immunology and data science is expected to accelerate discovery and optimize platform performance [2] Company Developments - The appointment of Dr. Wieckowski comes at a crucial time as Vaximm advances its lead candidate, VXM01, into further clinical development stages while exploring new targets [3] - Dr. Wieckowski will lead strategic enhancements to Vaximm's VXM platform, aiming to strengthen and expand its capabilities [3][4] R&D Strategy - Dr. Wieckowski has been integral to Vaximm's R&D strategy, significantly contributing to the development of VXM01 in oncology [4] - His leadership is anticipated to ensure a rigorous, data-driven evolution of Vaximm's core platform, enabling expansion into various oncology and non-oncology indications [4] Company Background - Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc., focusing on oral T-cell immunotherapy using live, attenuated bacterial vectors [5] - The lead candidate VXM01 targets VEGFR-2 and has shown clinical activity and safety across multiple cancer indications [5] Parent Company Overview - OSR Holdings, Inc. is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness through its subsidiaries [6]